The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: A Northern Finland 1966 Birth Cohort Study

References

• Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the study of Obesity. 2004. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 27, 2. 596–601
   Google Scholar
• Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502–508
   PubMed Web of Science ®Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of excess mortality of schizophrenia. Br J Psychiatry 2001; 177: 212–217
   Google Scholar
• Correll CU, Fredericksson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007; 89: 91–100
   PubMed Web of Science ®Google Scholar
• De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87–93
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophrenia Res 2008; 101: 295–303
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summery of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497
   PubMed Web of Science ®Google Scholar
• Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005; 66: 183–194
   PubMed Web of Science ®Google Scholar
• Grundy SM. Metabolic syndrome: A multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399–404
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Circulation 2005; 112: e285–290
   Web of Science ®Google Scholar
• Heilä H, Haukka J, Suvisaari J, Lönnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 2005; 35: 725–732
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575–579
   PubMed Web of Science ®Google Scholar
• Hägg S, Lindblom Y, Mjorndal T, Adolfson R. High prevalence of metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21: 93–98
   PubMed Web of Science ®Google Scholar
• Isohanni M, Mäkikyrö T, Moring J, Räsänen P, Hakko H, Partanen U, et al. A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort: clinical and research diagnosis of schizophrenia. Soc Psychiatr Psychiatr Epidemiol 1997; 32: 303–308
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular mortality and morbidity associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689
   PubMed Web of Science ®Google Scholar
• Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64(Suppl 12)1–100
   Google Scholar
• Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Rogers WJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women. Circulation 2004; 109: 706–713
   PubMed Web of Science ®Google Scholar
• Koponen H, Saari K, Savolainen M, Isohanni M. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication. A review. Eur Arch Psychiatry Clin Neurosci 2002; 252: 294–298
   PubMed Web of Science ®Google Scholar
• Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163: 1273–1276
   PubMed Web of Science ®Google Scholar
• Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–1349
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Nasrallah HA, Goff DC, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32
   PubMed Web of Science ®Google Scholar
• Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs 2004; 64(7)701–723
   PubMed Web of Science ®Google Scholar
• Mortensen PB. Mortality and physical illness in schizophrenia. The epidemiology of schizophrenia, RM Murray, PB Jones, E Susser, J Van Os, M Cannon. Cambridge University Press, Cambridge 2003
   Google Scholar
• Rantakallio P. Groups at risk in low birth weight infants and perinatal mortality. Acta Paediatr Scand 1969; 193(Suppl)1–71
   Google Scholar
• Saari K, Lindeman S, Viilo K, Isohanni M, Järvelin M-R, Lauren L, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 Birth Cohort Study. 2005; 66: 559–563
   Google Scholar
• Sacks FM. Metabolic syndrome: epidemiology and consequences. J Clin Psychiatry 2004; 65(Suppl 18)3–12
   PubMedGoogle Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007; 64: 1123–1131
   PubMed Web of Science ®Google Scholar
• Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005; 162: 1217–1221
   PubMed Web of Science ®Google Scholar
• Suvisaari JM, Saari SI, Perälä J, Suvisaari JVJ, Härkänen T, Lönnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007; 68: 1045–1055
   PubMed Web of Science ®Google Scholar